The Prevalence of Age-Related Macular Degeneration in Asians, Ophthalmology, vol.117, issue.5, pp.921-928, 2010. ,
DOI : 10.1016/j.ophtha.2009.10.007
The Five-year Incidence and Progression of Age-related Maculopathy, Ophthalmology, vol.104, issue.1, 1997. ,
DOI : 10.1016/S0161-6420(97)30368-6
The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration11The authors have no proprietary interest in any aspect of this study., Ophthalmology, vol.106, issue.5, pp.910-919, 1999. ,
DOI : 10.1016/S0161-6420(99)00509-6
The Prevalence of Age-related Maculopathy in the Rotterdam Study, Ophthalmology, vol.102, issue.2, pp.205-215, 1995. ,
DOI : 10.1016/S0161-6420(95)31034-2
Risk Factors of Age-related Maculopathy in a Population 70 Years of Age or Older, Ophthalmology, vol.103, issue.6, 1996. ,
DOI : 10.1016/S0161-6420(96)30593-9
Age-Related Macular Degeneration, Drugs & Aging, vol.119, issue.10, pp.101-134, 2002. ,
DOI : 10.2165/00002512-200219020-00003
Focal Inner Retinal Hemorrhages in Patients with Drusen, RETINA, vol.23, issue.6, pp.741-51, 2003. ,
DOI : 10.1097/00006982-200312000-00001
TYPE 3 NEOVASCULARIZATION, Retina, vol.28, issue.2, pp.201-212, 2008. ,
DOI : 10.1097/IAE.0b013e3181669504
Overexpression of Vascular Endothelial Growth Factor (VEGF) in the Retinal Pigment Epithelium Leads to the Development of Choroidal Neovascularization, The American Journal of Pathology, vol.157, issue.1, pp.135-179, 2000. ,
DOI : 10.1016/S0002-9440(10)64525-7
Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti???Vascular Endothelial Growth Factor Antibody Fragment, Archives of Ophthalmology, vol.120, issue.3, pp.338-384, 1960. ,
DOI : 10.1001/archopht.120.3.338
Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors, Proceedings of the National Academy of Sciences, vol.102, issue.8, pp.2934-2943, 2005. ,
DOI : 10.1073/pnas.0500180102
VEGF and the quest for tumour angiogenesis factors, Nature Reviews Cancer, vol.120, issue.10, pp.795-803, 2002. ,
DOI : 10.1038/nrc909
Endothelial cells and VEGF in vascular development, Nature, vol.296, issue.7070, pp.937-982, 2005. ,
DOI : 10.1038/nature04479
VEGF-targeted therapy: mechanisms of anti-tumour activity, Nature Reviews Cancer, vol.119, issue.8, pp.579-91, 2008. ,
DOI : 10.1038/nrc2403
Tumor angiogenesis: molecular pathways and therapeutic targets, Nature Medicine, vol.10, issue.11, pp.1359-70, 2011. ,
DOI : 10.1038/nm.1971
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration, Annual Review of Medicine, vol.58, issue.1, pp.491-504, 2007. ,
DOI : 10.1146/annurev.med.58.061705.145635
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration, Cochrane Database Syst Rev, vol.281, issue.2, p.5139, 2014. ,
DOI : 10.1002/14651858.CD005139.pub3
The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology, Mayo Clinic Proceedings, vol.87, issue.1, pp.77-88 ,
DOI : 10.1016/j.mayocp.2011.10.001
Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2, Arch Ophthalmol Chic Ill Feb, vol.119, issue.2, pp.198-207, 1960. ,
Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition, Progress in Retinal and Eye Research, vol.22, issue.6, pp.721-769, 2003. ,
DOI : 10.1016/j.preteyeres.2003.08.001
Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment, PLoS ONE, vol.109, issue.6, p.101072, 2014. ,
DOI : 10.1371/journal.pone.0101072.t003
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration, New England Journal of Medicine, vol.355, issue.14, pp.1432-1476, 2006. ,
DOI : 10.1056/NEJMoa062655
Ranibizumab for Neovascular Age-Related Macular Degeneration, New England Journal of Medicine, vol.355, issue.14, pp.1419-1450, 2006. ,
DOI : 10.1056/NEJMoa054481
Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study, Ophthalmology, vol.118, issue.5, pp.831-840, 2011. ,
DOI : 10.1016/j.ophtha.2010.09.004
Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2, American Journal of Ophthalmology, vol.150, issue.3, pp.315-339, 2010. ,
DOI : 10.1016/j.ajo.2010.04.011
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration, Ophthalmology, vol.119, issue.6, pp.1175-83, 2012. ,
DOI : 10.1016/j.ophtha.2011.12.016
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration, Ophthalmology, vol.119, issue.7, pp.1388-98, 2012. ,
DOI : 10.1016/j.ophtha.2012.03.053
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration, Ophthalmology, vol.120, issue.5, pp.1046-56, 2013. ,
DOI : 10.1016/j.ophtha.2012.10.014
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial, Ophthalmology, vol.119, issue.7, pp.1399-411, 2012. ,
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact, Ophthalmology, vol.117, issue.11, pp.2134-2174, 2010. ,
DOI : 10.1016/j.ophtha.2010.02.032
ANTI-VEGF TREATMENT IN NEOVASCULAR AGE???RELATED MACULAR DEGENERATION, Retina, vol.34, issue.8, pp.1531-1539, 2014. ,
DOI : 10.1097/IAE.0000000000000134
Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen, American Journal of Ophthalmology, vol.159, issue.1, pp.3-8, 2015. ,
DOI : 10.1016/j.ajo.2014.09.011
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration, British Journal of Ophthalmology, vol.119, issue.(5 Suppl), pp.2015-306987, 2015. ,
DOI : 10.1136/bjophthalmol-2015-306987
Predicted biological activity of intravitreal VEGF Trap, British Journal of Ophthalmology, vol.92, issue.5, pp.667-675, 2008. ,
DOI : 10.1136/bjo.2007.134874
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, vol.28, issue.281, pp.171-85, 2012. ,
DOI : 10.1007/s10456-011-9249-6
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration, Ophthalmology, vol.119, issue.12, pp.2537-2585, 2012. ,
DOI : 10.1016/j.ophtha.2012.09.006
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration, Ophthalmology, vol.121, issue.1, pp.193-201, 2014. ,
DOI : 10.1016/j.ophtha.2013.08.011
Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting, American Journal of Ophthalmology, vol.148, issue.3, pp.409-422, 2009. ,
DOI : 10.1016/j.ajo.2009.04.001
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE, Retina, vol.33, issue.3, pp.474-81, 2013. ,
DOI : 10.1097/IAE.0b013e31827b6324
Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study, Graefe's Archive for Clinical and Experimental Ophthalmology, vol.143, issue.4, pp.521-528, 2011. ,
DOI : 10.1007/s00417-010-1553-0
Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany], Ophthalmol Z Dtsch Ophthalmol Ges, vol.112, issue.3, pp.246-54, 2015. ,
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration, British Journal of Ophthalmology, vol.120, issue.2, pp.220-226, 2015. ,
DOI : 10.1136/bjophthalmol-2014-305327
Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme, British Journal of Ophthalmology, vol.27, issue.9, pp.1161-1168, 2013. ,
DOI : 10.1136/bjophthalmol-2013-303232
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE, Retina, vol.35, issue.9, pp.1743-1752, 2015. ,
DOI : 10.1097/IAE.0000000000000548
Enquête de " vraie vie " -Premier bilan d'utilisation d'Eylea dans la DMLA humide. Réflexions Ophtalmologiques, p.2834, 2015. ,
First-Year Visual Acuity Outcomes in the United Kingdom of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration, Ophthalmology [Internet], 2015. ,
NEAR VISION OUTCOME IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH AFLIBERCEPT, Retina, vol.36, issue.9, 2016. ,
DOI : 10.1097/IAE.0000000000000978
Intravitreal aflibercept (A-IVI) for the treatment of neovascular age-related macular degeneration (nv-AMD): one year experience, Hell J Nucl Med, vol.18, issue.1, pp.29-32, 2015. ,
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA, PLOS ONE, vol.6, issue.7, 2015. ,
DOI : 10.1371/journal.pone.0133968.s002
Retrospective Analysis of First-Line Anti-Vascular Endothelial Growth Factor Treatment Patterns in Wet Age-Related Macular Degeneration, Advances in Therapy, vol.45, issue.6, pp.1111-1138, 2013. ,
DOI : 10.1007/s12325-013-0078-4
Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life, PLOS ONE, vol.121, issue.1, p.135050, 2015. ,
DOI : 10.1371/journal.pone.0135050.s001
??valuation de l???efficacit?? de l???aflibercept comme traitement de la d??g??n??rescence maculaire li??e ?? l?????ge exsudative chez des patients na??fs et ????switch??s????. ?? propos de 86??cas, Journal Fran??ais d'Ophtalmologie, vol.39, issue.3, pp.255-60, 2016. ,
DOI : 10.1016/j.jfo.2015.10.009
Two Year Visual Acuity Outcomes of eyes with Neovascular Age-related Macular Degeneration treated with Aflibercept, National Aflibercept Users Group ,
Efficacy of aflibercept in treatment naïve neovasculat age-related macular degeneration : one-year real world outcomes, pp.2015-4613 ,
Efficacy of Aflibercept in treatment-naïve neovascular age-related macular degenration : two-year real world oucomes, 2016. ,
Real Life of Aflibercept In France : RAINBOW data on file, ARVO, vol.2016, pp.524-0161 ,
Guymer Robyn, et al. 12 months outcomes of ranibizumab v. aflibercept for neovascular AMD : Observational Study data, 2016. ,
Traitement de la d??g??n??rescence maculaire li??e ?? l?????ge??: avis d???experts et algorithme th??rapeutique, Journal Fran??ais d'Ophtalmologie, vol.38, issue.7, pp.639-684, 2015. ,
DOI : 10.1016/j.jfo.2015.06.001